{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:58:13Z","timestamp":1791925093443,"version":"4.3.4"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T00:00:00Z","timestamp":1655164800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005294","name":"MASSACHUSETTS GENERAL HOSPITAL","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005294","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.semarthrit.2022.152010","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T19:00:00Z","timestamp":1650049200000},"page":"152010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":100,"special_numbering":"C","title":["The glucocorticoid toxicity index: Measuring change in glucocorticoid toxicity over time"],"prefix":"10.1016","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6588-9435","authenticated-orcid":false,"given":"John H.","family":"Stone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Jane","family":"McDowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.W.","family":"Jayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Merkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Robson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi J.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huibin","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pirow","family":"Bekker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam G.","family":"Heaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.semarthrit.2022.152010_bib0001","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.semarthrit.2016.10.001","article-title":"Incidence of outcomes potentially associated with corticosteroid therapy in patients with giant cell arteritis","volume":"46","author":"Wilson","year":"2017","journal-title":"Semin Arthr Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152010_bib0002","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.semarthrit.2016.11.006","article-title":"Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysis","volume":"46","author":"Wilson","year":"2017","journal-title":"Semin Arthr Rheum"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.152010_bib0003","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1136\/ard.2009.124958","article-title":"Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice","volume":"69","author":"Van der Goes","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152010_bib0004","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jclinepi.2013.12.009","article-title":"Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria","volume":"67","author":"Johnson","year":"2014","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.152010_bib0005","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","article-title":"2015 Gout classification criteria: an American College of Rheumatology\/European league against rheumatism collaborative initiative","volume":"74","author":"Neogi","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.semarthrit.2022.152010_bib0006","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1002\/art.27580","article-title":"The 2010 American College of Rheumatology\/European league against rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report","volume":"62","author":"Neogi","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2022.152010_bib0007","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/BOR.0000000000000259","article-title":"Pros and cons of conjoint analysis of discrete choice experiments to define classification and response criteria in rheumatology","volume":"28","author":"Taylor","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152010_bib0008","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1136\/annrheumdis-2018-214685","article-title":"Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus","volume":"78","author":"Tedeschi","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152010_bib0009","article-title":"Identifying potential classification criteria for calcium pyrophosphate deposition disease (CPPD): Item generation and item reduction","author":"Tedeschi","year":"2021","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152010_bib0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/art.41120","article-title":"The 2019 ACR\/EULAR classification criteria for IgG4-related disease","volume":"72","author":"Wallace","year":"2020","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152010_bib0011","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jaip.2020.08.032","article-title":"Quantification of glucocorticoid-associated morbidity in severe asthma using the glucocorticoid toxicity index","volume":"9","author":"McDowell","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.semarthrit.2022.152010_bib0012","article-title":"Glucocorticoid toxicity reduction with mepolizumab using the glucocorticoid toxicity index","author":"McDowell","year":"2021","journal-title":"Eur Resp J"},{"key":"10.1016\/j.semarthrit.2022.152010_bib0013","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/annrheumdis-2016-210002","article-title":"Development of a glucocorticoid toxicity index (GTI) using multi-criteria decision analysis","volume":"76","author":"Miloslavsky","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152010_bib0014","doi-asserted-by":"crossref","first-page":"e16664","DOI":"10.2196\/16664","volume":"9","author":"Merkel","year":"2020","journal-title":"JMIR Res Protoc"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.152010_bib0015","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"For the ADVOCATE study group. Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2022.152010_bib0016","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1136\/ard.2009.114579","article-title":"Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR recommendations on the management of systemic glucocorticoid therapy in rheumatic disease","volume":"69","author":"Van der Goes","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152010_bib0017","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13075-015-0658-6","article-title":"Approaches for estimating minimal clinically important differences in systemic lupus erythematosus","volume":"17","author":"Rai","year":"2015","journal-title":"Arthritis Research & Therapy"},{"key":"10.1016\/j.semarthrit.2022.152010_bib0018","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.spinee.2007.01.008","article-title":"Understanding the minimum clinically important difference: a review of concepts and methods","volume":"7","author":"Copay","year":"2007","journal-title":"Spine J"},{"key":"10.1016\/j.semarthrit.2022.152010_bib0019","doi-asserted-by":"crossref","unstructured":"Patel NJ, Zhang Y, Jayne DRW, Merkel PA, Yue H, Bekker P, Stone JH. Differences between avacopan and prednisone for treatment of ANCA-associated vasculitis at different thresholds of glucocorticoid toxicity. (Abstract accepted for presentation at European League Against Rheumatism 2022).","DOI":"10.1136\/annrheumdis-2022-eular.3702"}],"updated-by":[{"DOI":"10.1016\/j.semarthrit.2024.152496","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000}},{"DOI":"10.1016\/j.semarthrit.2022.152124","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000}}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222000610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222000610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T08:28:45Z","timestamp":1708763325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017222000610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":19,"alternative-id":["S0049017222000610"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152010","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The glucocorticoid toxicity index: Measuring change in glucocorticoid toxicity over time","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152010"}}